1. TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
   Sofia Valente et al, 2023, Cancers CrossRef
2. Identification, characterization, expression profiles of OlHavcr2 in medaka (Oryzias latipes)
   Emile Nibona et al, 2019, General and Comparative Endocrinology CrossRef
3. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
   Wenxiang Zhang et al, 2021, Frontiers in Oncology CrossRef
4. The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress
   Hossein Javid et al, 2023, Journal of Cellular Biochemistry CrossRef
5. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer
   Bum-Sup Jang et al, 2020, Radiotherapy and Oncology CrossRef
6. Varied functions of immune checkpoints during cancer metastasis
   Ali Safarzadeh et al, 2021, Cancer Immunology, Immunotherapy CrossRef
7. Significance of TIM-3 expression by CD4+ and CD8+ T lymphocytes in tumor-draining lymph nodes from patients with breast cancer
   Sahar Shariati et al, 2020, Molecular Immunology CrossRef
8. Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
   Sebastian Chrétien et al, 2019, Cancers CrossRef
9. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis
   Emily Wingrove et al, 2019, Cell Reports CrossRef
10. The Emerging Role of T-Cell Immunoglobulin Mucin-3 in Breast Cancer: A Promising Target For Immunotherapy
    Yizi Cong et al, 2021, Frontiers in Oncology CrossRef
11. Immunotherapy in breast cancer: Current status and future directions
    Amrita Basu et al, 2019, Immunotherapy of Cancer CrossRef
12. Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints
    Dharmindra Dulal et al, 2023, Cancers CrossRef
13. TIM-3 expression in breast cancer
    Samantha Burugu et al, 2018, OncoImmunology CrossRef
14. Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors
    Elif Acar et al, 2022, Clinical Breast Cancer CrossRef
15. Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer
    Umut Kina Kilicaslan et al, 2024, Surgical Oncology CrossRef
16. TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation
    Kui Zang et al, 2021, Frontiers in Oncology CrossRef
17. Prognostic significance of the expression levels of T‑cell immunoglobulin mucin‑3 and its ligand galectin‑9 for relapse‑free survival in triple‑negative breast cancer
    Katsuhiro Yoshikawa et al, 2022, Oncology Letters CrossRef
18. T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer
    Kyung Do Byun et al, 2018, Journal of Breast Cancer CrossRef
19. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
    Natalia Sauer et al, 2023, Cancer Immunology, Immunotherapy CrossRef
20. Immune microenvironment in different molecular subtypes of ductal breast carcinoma
    Mona Sadeghalvad et al, 2021, Breast Cancer Research and Treatment CrossRef
21. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
    Baran Mollavelioglu et al, 2022, World Journal of Surgical Oncology CrossRef